We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sumanta Pal

Sumanta Kumar Pal MD

Clinical Professor, Department of Medical Oncology & Therapeutics Research; Co-Director, Kidney Cancer Program, City of Hope, Duarte, California

Biographical Sketch:

Dr. Sumanta (Monty) Pal is a medical oncologist and an internationally recognized leader in the area of genitourinary cancers. He is a clinical professor in the Department of Medical Oncology & Therapeutics Research at City of Hope in Duarte, California, where he is co-director of the kidney cancer program and heads up the kidney and bladder cancer disease team at that institution. Dr. Pal entered medical school at the age of 17, and received his MD from the UCLA School of Medicine, where he developed his interest in cancer research. After residency training in internal medicine at the UCLA Medical Center in Los Angeles, he completed a fellowship in medical oncology at City of Hope’s comprehensive cancer center, where he has remained on faculty since 2009.

Over that time, he has published more than 300 PubMed-cited articles, which have been featured in prominent journals, including Cancer Discovery, Journal of Clinical Oncology, The Lancet Oncology, Cancer Cell, and European Urology, and has presented his work at numerous international meetings. His goal is to translate laboratory discoveries as quickly and efficiently as possible into tangible benefits for patients. Dr. Pal is the lead investigator on multiple trials, ranging from early phase I experiences to late phase III studies. He has received grants from the National Institute of Health, the Comprehensive Cancer Network, SWOG Cancer Research Network, and multiple other leading entities in support of his research.

Positions:

Clinical Professor, Department of Medical Oncology & Therapeutics Research; Co-Director, Kidney Cancer Program, City of Hope, Duarte, California

Degrees:

MD: UCLA School of Medicine, Los Angeles, California

Postgraduate Training:

Fellowship (hematology/oncology): City of Hope/Harbor-UCLA Medical Center, Los Angeles, California

Research Interests:

Genitourinary cancers; translational science

Disclosures

Sumanta Kumar Pal, MD serves as a consultant to Pfizer, Inc., Novartis, AVEO Pharmaceuticals, Inc., Genentech, Inc., Exelixis, Bristol-Myers Squibb Company, and Astellas Pharma, Inc.